According to a newly-inked deal between the two companies, Glooko plans to provide its diabetes data management platform to Valeritas (NSDQ:VLRX) for use with the medtech company’s next-gen V-Go insulin delivery device.
Valeritas’ V-GO SIM device is an investigational accessory that the company said will snap onto its existing insulin delivery devices. The product is designed to transmit data from the delivery device to an app on the user’s smartphone.
“We are thrilled to be partnering with Glooko and excited to be able to offer Glooko’s market-leading, diabetes data management platform to our customers when we introduce our V-Go SIM technology throughout the U.S. in the first half of 2019,” president & CEO John Timberlake said in prepared remarks.
“We are excited to bring V-Go’s easy and convenient insulin delivery solution coupled with the V-Go SIM technology onto the Glooko platform,” Glooko’s newly-named CEO Russ Johannesson added.
“We believe the combination of our flagship product V-Go, combined with our Bluetooth technology enabled V-Go SIM and Glooko’s diabetes data management platform will allow adult patients with diabetes and their healthcare providers to optimize each patient’s diabetes management and care plan,” Timberlake added.
Valeritas announced earlier this week that it landed an exclusive distribution deal for its V-Go device in Australia and New Zealand.
Want to stay on top of DDBN content? Sign up for our e-mail newsletter for a weekly dose of drug-device news.